Ind-Swift Ltd, a Rs 275-crore pharma company based in Chandigarh, has achieved satisfactory performance during the third quarter ended December 2006. Its sales increased by 38.3 per cent to Rs 108 crore from Rs 78.10 crore in the corresponding period of last year. Higher interest and depreciation provisions, however, put pressure on net profit, which increased by 8.4 per cent to Rs 6.73 crore from Rs 6.21 crore. The earning per share reached at Rs 1.81 from Rs 1.67 in the last period.

For the nine months period ended December 2006, its sales moved up by 25.3 per cent to Rs 282.44 crore from Rs 225.38 crore in the similar period of last year. The net profit improved o Rs 17.34 core from Rs 16.42 crore, a growth of 5.6 per cent. The company achieved sales of Rs 274.91 crore for the fully year ended March 2006 and earned a net profit of Rs 17.27 crore.

The company commissioned its three new finished dosage facilities at Jammu, Derabassi and Baddi during the quarter ended December 2006. Another new facility at Baddi is expected to be operational in the next quarter. The company has received ISO9001-2000 QMS certification for its product facilities.